Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

E-SCOPE: A Strategic Approach to Identify and Accelerate Implementation of Evidence-based Best Practices.

Henry SL, Mohan Y, Whittaker JL, Koster MA, Schottinger JE, Kanter MH.

Med Care. 2019 Oct;57 Suppl 10 Suppl 3:S239-S245. doi: 10.1097/MLR.0000000000001191.

PMID:
31517794
2.

Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study.

Selby K, Jensen CD, Zhao WK, Lee JK, Slam A, Schottinger JE, Bacchetti P, Levin TR, Corley DA.

Clin Transl Gastroenterol. 2019 Feb;10(2):e00010. doi: 10.14309/ctg.0000000000000010.

3.

Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings.

Lee JK, Jensen CD, Levin TR, Zauber AG, Schottinger JE, Quinn VP, Udaltsova N, Zhao WK, Fireman BH, Quesenberry CP, Doubeni CA, Corley DA.

JAMA Intern Med. 2019 Feb 1;179(2):153-160. doi: 10.1001/jamainternmed.2018.5565.

PMID:
30556824
4.

Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study.

Selby K, Jensen CD, Lee JK, Doubeni CA, Schottinger JE, Zhao WK, Chubak J, Halm E, Ghai NR, Contreras R, Skinner C, Kamineni A, Levin TR, Corley DA.

Ann Intern Med. 2018 Oct 2;169(7):439-447. doi: 10.7326/M18-0244. Epub 2018 Sep 18.

5.

Colorectal Cancer Screening Participation Among Asian Americans Overall and Subgroups in an Integrated Health Care Setting with Organized Screening.

Ghai NR, Jensen CD, Corley DA, Doubeni CA, Schottinger JE, Zauber AG, Lee AT, Contreras R, Levin TR, Lee JK, Quinn VP.

Clin Transl Gastroenterol. 2018 Sep 21;9(9):186. doi: 10.1038/s41424-018-0051-2.

6.

Index colonoscopy-related risk factors for postcolonoscopy colorectal cancers.

Tollivoro TA, Jensen CD, Marks AR, Zhao WK, Schottinger JE, Quinn VP, Ghai NR, Zauber AG, Doubeni CA, Levin TR, Fireman B, Quesenberry CP, Corley DA.

Gastrointest Endosc. 2019 Jan;89(1):168-176.e3. doi: 10.1016/j.gie.2018.08.023. Epub 2018 Aug 23.

PMID:
30144415
7.

Developing innovative models of care for cancer survivors: use of implementation science to guide evaluation of appropriateness and feasibility.

Hahn EE, Munoz-Plaza CE, Schottinger JE, Brasfield FM, Gould MK, Parry C.

Support Care Cancer. 2019 May;27(5):1737-1745. doi: 10.1007/s00520-018-4425-5. Epub 2018 Aug 24.

PMID:
30143893
8.

Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population.

Levin TR, Corley DA, Jensen CD, Schottinger JE, Quinn VP, Zauber AG, Lee JK, Zhao WK, Udaltsova N, Ghai NR, Lee AT, Quesenberry CP, Fireman BH, Doubeni CA.

Gastroenterology. 2018 Nov;155(5):1383-1391.e5. doi: 10.1053/j.gastro.2018.07.017. Epub 2018 Jul 19.

PMID:
30031768
9.

Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Schottinger JE, Marks AR, Zhao WK, Ghai NR, Lee AT, Contreras R, Quesenberry CP, Fireman BH, Levin TR.

JAMA. 2017 Apr 25;317(16):1631-1641. doi: 10.1001/jama.2017.3634.

10.

Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.

Haque R, Shi J, Chung J, Xu X, Avila C, Campbell C, Ahmed SA, Chen L, Schottinger JE.

J Am Pharm Assoc (2003). 2017 May - Jun;57(3):303-310.e2. doi: 10.1016/j.japh.2017.01.004. Epub 2017 Mar 1.

11.

Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.

Spence MM, Hui RL, Chang JT, Schottinger JE, Millares M, Rashid N.

J Manag Care Spec Pharm. 2017 Feb;23(2):195-205. doi: 10.18553/jmcp.2017.23.2.195.

12.

Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature.

Doubeni CA, Jensen CD, Fedewa SA, Quinn VP, Zauber AG, Schottinger JE, Corley DA, Levin TR.

J Am Board Fam Med. 2016 Nov 12;29(6):672-681. doi: 10.3122/jabfm.2016.06.160060.

13.

Anxiety, Culture, and Expectations: Oncologist-Perceived Factors Associated With Use of Nonrecommended Serum Tumor Marker Tests for Surveillance of Early-Stage Breast Cancer.

Hahn EE, Munoz-Plaza C, Wang J, Garcia Delgadillo J, Schottinger JE, Mittman BS, Gould MK.

J Oncol Pract. 2017 Jan;13(1):e77-e90. doi: 10.1200/JOP.2016.014076. Epub 2016 Nov 15.

PMID:
27845868
14.

Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System.

Mehta SJ, Jensen CD, Quinn VP, Schottinger JE, Zauber AG, Meester R, Laiyemo AO, Fedewa S, Goodman M, Fletcher RH, Levin TR, Corley DA, Doubeni CA.

J Gen Intern Med. 2016 Nov;31(11):1323-1330. doi: 10.1007/s11606-016-3792-1. Epub 2016 Jul 13.

15.

Identifying Subsequent Therapies in Patients with Advanced Non-Small Cell Lung Cancer and Factors Associated with Overall Survival.

Afanasjeva J, Hui RL, Spence MM, Chang J, Schottinger JE, Millares M, Rashid N.

Pharmacotherapy. 2016 Oct;36(10):1065-1074. doi: 10.1002/phar.1826. Epub 2016 Sep 25.

PMID:
27521530
16.

Using Literature Review and Structured Hybrid Electronic/ Manual Mortality Review to Identify System-Level Improvement Opportunities to Reduce Colorectal Cancer Mortality.

Schottinger JE, Kanter MH, Litman KC, Lau H, Schwartz GE, Brasfield FM, Alshak NS, Difronzo LA.

Jt Comm J Qual Patient Saf. 2016 Jul;42(7):303-10.

PMID:
27301833
17.

Cardiovascular Disease After Aromatase Inhibitor Use.

Haque R, Shi J, Schottinger JE, Chung J, Avila C, Amundsen B, Xu X, Barac A, Chlebowski RT.

JAMA Oncol. 2016 Dec 1;2(12):1590-1597. doi: 10.1001/jamaoncol.2016.0429.

PMID:
27100398
18.

Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.

Kwan ML, Shi JM, Habel LA, Song J, Chung JW, Avila CC, Schottinger JE, Cheetham TC, Fletcher SW, Haque R.

Breast Cancer Res Treat. 2016 Apr;156(2):379-89. doi: 10.1007/s10549-016-3763-6. Epub 2016 Mar 22.

PMID:
27002508
19.

Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems.

Chubak J, Garcia MP, Burnett-Hartman AN, Zheng Y, Corley DA, Halm EA, Singal AG, Klabunde CN, Doubeni CA, Kamineni A, Levin TR, Schottinger JE, Green BB, Quinn VP, Rutter CM; PROSPR consortium.

Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):344-50. doi: 10.1158/1055-9965.EPI-15-0470.

20.

Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.

Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Zhao WK, Marks AR, Schottinger JE, Ghai NR, Lee AT, Contreras R, Klabunde CN, Quesenberry CP, Levin TR, Mysliwiec PA.

Ann Intern Med. 2016 Apr 5;164(7):456-63. doi: 10.7326/M15-0983. Epub 2016 Jan 26.

21.

Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.

Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, Avila C, Kleinman K, Habel LA, Fletcher SW, Kwan ML.

J Natl Cancer Inst. 2015 Dec 1;108(3). doi: 10.1093/jnci/djv337. Print 2016 Mar.

22.

Quality of preventive care before and after prostate cancer diagnosis.

Wallner LP, Slezak JM, Quinn VP, Loo RK, Schottinger JE, Bastani R, Jacobsen SJ.

J Mens Health. 2015 May 1;11(5):14-21.

23.

Integration Alone Does Not Reduce Health Care Disparities.

Kanter MH, Schottinger JE, Copeland R.

J Clin Oncol. 2015 Oct 20;33(30):3519. doi: 10.1200/JCO.2015.61.5047. Epub 2015 Jul 27. No abstract available.

PMID:
26215965
24.

Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012.

Wallner LP, Hsu JW, Loo RK, Palmer-Toy DE, Schottinger JE, Jacobsen SJ.

Urology. 2015 Sep;86(3):498-505. doi: 10.1016/j.urology.2015.04.063. Epub 2015 Jun 27.

PMID:
26123517
25.

Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model.

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Jensen CD, van der Meulen MP, Levin TR, Quinn VP, Schottinger JE, Zauber AG, Corley DA, van Ballegooijen M.

JAMA. 2015 Jun 16;313(23):2349-58. doi: 10.1001/jama.2015.6251.

26.

A hybrid approach to identify subsequent breast cancer using pathology and automated health information data.

Haque R, Shi J, Schottinger JE, Ahmed SA, Chung J, Avila C, Lee VS, Cheetham TC, Habel LA, Fletcher SW, Kwan ML.

Med Care. 2015 Apr;53(4):380-5. doi: 10.1097/MLR.0000000000000327.

PMID:
25769058
27.

Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.

Chlebowski RT, Schottinger JE, Shi J, Chung J, Haque R.

Cancer. 2015 Jul 1;121(13):2147-55. doi: 10.1002/cncr.29332. Epub 2015 Mar 10.

28.

Metformin and breast and gynecological cancer risk among women with diabetes.

Soffer D, Shi J, Chung J, Schottinger JE, Wallner LP, Chlebowski RT, Lentz SE, Haque R.

BMJ Open Diabetes Res Care. 2015 Jan 24;3(1):e000049. doi: 10.1136/bmjdrc-2014-000049. eCollection 2015.

29.

Adjusting for patient demographics has minimal effects on rates of adenoma detection in a large, community-based setting.

Jensen CD, Doubeni CA, Quinn VP, Levin TR, Zauber AG, Schottinger JE, Marks AR, Zhao WK, Lee JK, Ghai NR, Schneider JL, Fireman BH, Quesenberry CP, Corley DA.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):739-46. doi: 10.1016/j.cgh.2014.10.020. Epub 2014 Oct 25.

30.

Adenoma detection rate and risk of colorectal cancer and death.

Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, Zauber AG, de Boer J, Fireman BH, Schottinger JE, Quinn VP, Ghai NR, Levin TR, Quesenberry CP.

N Engl J Med. 2014 Apr 3;370(14):1298-306. doi: 10.1056/NEJMoa1309086.

31.

Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop.

Balogh EP, Bach PB, Eisenberg PD, Ganz PA, Green RJ, Gruman JC, Nass SJ, Newcomer LN, Ramsey SD, Schottinger JE, Shih YT.

J Oncol Pract. 2013 Nov;9(6S):54s-59s. doi: 10.1200/JOP.2013.001123.

PMID:
29431037
32.

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.

Haque R, Ahmed SA, Fisher A, Avila CC, Shi J, Guo A, Craig Cheetham T, Schottinger JE.

Cancer Med. 2012 Dec;1(3):318-27. doi: 10.1002/cam4.37. Epub 2012 Sep 26.

33.

Identifying primary and recurrent cancers using a SAS-based natural language processing algorithm.

Strauss JA, Chao CR, Kwan ML, Ahmed SA, Schottinger JE, Quinn VP.

J Am Med Inform Assoc. 2013 Mar-Apr;20(2):349-55. doi: 10.1136/amiajnl-2012-000928. Epub 2012 Jul 21.

34.

Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.

Spence MM, Hui RL, Chan J, Schottinger JE.

Ann Pharmacother. 2010 Sep;44(9):1384-8. doi: 10.1345/aph.1P152. Epub 2010 Aug 3.

PMID:
20682850
35.

Critical appraisal of clinical studies: an example from computed tomography screening for lung cancer.

Emptage NP, Koster MA, Schottinger JE, Petitti DB.

Perm J. 2007 Spring;11(2):81-5. No abstract available.

36.

Trials of commercial reagents in anion-exchange coagulation procedures: ortho diagnostics.

Branson HE, Schottinger JE, Fagin AR, Puri SL, Roohk V.

Am J Clin Pathol. 1984 Oct;82(4):432-5.

PMID:
6475839

Supplemental Content

Loading ...
Support Center